perturbing dna repair pathways to enhance immune
 responsiveness in prostate cancer

The pharmaceutical industry has focused on developing drugs that target critical tumor-promoting pathways, including DNA repair pathways, within cancer cells. However, the impact of these drugs on the activation and/or trafficking of immune cells into the cancer microenvironment remains poorly understood. In this proposal, we aim to elucidate the effect of drugs known to inhibit the DNA repair protein PARP, on the immune microenvironment within prostate cancer. We anticipate that a deeper understanding of the immune effects mediated by PARP inhibitors will lead to the development of novel combinations that make immunotherapy more effective in advanced prostate cancer.